Remogliflozin, formerly known as Remogliflozin A and GSK189074, is a potent inhibitor of sodium-glucose transporter 2 (SGLT2; Kis = 12.4 and 26 nM for human and rat SGLT2, respectively). References: Sadurní A, Kehr G, Ahlqvist M, Wernevik J, Sjogren HP, Kankkonen C, Knerr L, Gilmour R. Fluorine-Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 Inhibitors for Type II Diabetes. Chemistry. 2018 Feb 26;24(12):2832-2836. doi: 10.1002/chem.201705373. Epub 2017 Dec 20. PubMed PMID: 29211300.

纯度：≥98%

CAS：329045-45-6